Harte Hanks (HHS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
12 Nov, 2025Executive summary
Q3 2025 revenue was $39.5 million, down 17% year-over-year, due to customer turnover, program conclusions, and timing in legacy contracts.
Net loss for Q3 2025 was $2.3 million ($0.31 per diluted share), compared to net income of $0.1 million ($0.02 per share) in Q3 2024; nine-month net loss was $3.0 million versus a $27.9 million loss in the prior year, which included a large pension termination charge.
Operating expenses decreased 14.7% year-over-year to $39.0 million, reflecting cost controls and restructuring.
Project Elevate transformation program continued, with $0.5 million in restructuring charges in Q3 and $1.5 million year-to-date, targeting $16 million in cost savings by 2026.
New partnership with Samsung and a new Greenville, SC facility signal pipeline replenishment and future growth.
Financial highlights
Q3 2025 revenue: $39.5 million (down 17% year-over-year); nine months: $119.7 million (down 13.3%).
Q3 2025 net loss: $2.3 million; nine months: $3.0 million net loss.
Q3 2025 basic and diluted EPS: $(0.31); nine months: $(0.41).
Cash and cash equivalents at September 30, 2025: $6.5 million; available credit facility: $24.0 million.
Positive working capital of $15.7 million supports operations.
Outlook and guidance
Management expects Q4 2025 to benefit from new business and client expansions, with sequential improvement anticipated.
Full-year 2025 is expected to deliver positive EBITDA, supported by cost reductions and operational efficiencies.
Pipeline conversion in Customer Care and Fulfillment is expected to drive results in Q4 and 2026.
Management expects further cost reductions from Project Elevate and continued focus on optimizing operations and technology investments.
No conditions or events raise substantial doubt about the company's ability to continue as a going concern for the next twelve months.
Latest events from Harte Hanks
- Positive EBITDA and improved net results in FY 2025 despite lower revenue and segment declines.HHS
Q4 202518 Mar 2026 - Q2 net loss of $27.8M from pension charge; Sales Services surged, cash strong, no debt.HHS
Q2 20242 Feb 2026 - Q3 revenue up 1.1% YoY; profit metrics declined; Q4 revenue expected to contract.HHS
Q3 202414 Jan 2026 - Shareholders to vote on board, executive pay, and auditor as company targets growth and innovation.HHS
Proxy Filing2 Dec 2025 - Beneficial ownership update adds Rosenbachs as 26.26% holders for 2025 meeting.HHS
Proxy Filing2 Dec 2025 - Revenue dropped 14.2% but net loss narrowed and EBITDA stayed positive in Q2 2025.HHS
Q2 20258 Aug 2025 - Revenue fell 8.6% to $41.6M, net loss widened, but liquidity and new business remain strong.HHS
Q1 20256 Jun 2025 - Net loss of $30.3M in 2024 driven by pension charges, despite improved cost structure.HHS
Q4 20245 Jun 2025